Editor sorry for drug cost article

The Web site of the student-run Harvard Health Policy Review is up and running after about a week of mysterious down time, and the journal's editor has apologized for running a controversial article without proper bias screening. linkurl:Rumors;http://www.gooznews.com/archives/001223.html circulated last week when the Review Web site was down that Harvard authorities had censored the publication of the article, which addressed a long-standing debate about the total cost for developing a drug, f

Written byAndrea Gawrylewski
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
The Web site of the student-run Harvard Health Policy Review is up and running after about a week of mysterious down time, and the journal's editor has apologized for running a controversial article without proper bias screening. linkurl:Rumors;http://www.gooznews.com/archives/001223.html circulated last week when the Review Web site was down that Harvard authorities had censored the publication of the article, which addressed a long-standing debate about the total cost for developing a drug, from the spring 2008 issue. The article, written by linkurl:Donald Light;http://sph.umdnj.edu/staff/staffDetail.cfm?tblPers_ID_pk=564 of the University of Medicine & Dentistry of New Jersey and linkurl:Rebecca Warburton;http://publicadmin.uvic.ca/faculty/warburton/index.htm of the University of Victoria, describes the authors' difficulty in publishing a critique of another article, which estimated drug development costs at $802 million and was published in 2003 in the Journal of Health Economics (JHE) by linkurl:Joseph DiMasi;http://csdd.tufts.edu/About/ResearchStaff.asp at Tufts Center for the Study of Drug Development. (For more background on the article click linkurl:here.);http://www.the-scientist.com/news/display/55101/) In response to the article, Richard Frank, one of the editors of the JHE, wrote Huang an Email, saying that the article in the Review was biased against him and his colleagues. "The site was temporarily taken down because we panicked," Huang wrote to the linkurl:Pharmalot blog;http://www.pharmalot.com/2008/10/the-case-of-the-disappearing-journal-article/ in an Email. "We thought that we might have inadvertently published something that was potentially very biased and/or unsubstantiated." Huang has since posted an linkurl:apology on the Web site;http://www.hhpr.org/currentissue/ stating that the editors of JHE had not been contacted to confirm statements made in the article by Light and Warburton. The Review reposted the original version of the article. "We are apologizing that the article was edited in an
 unbalanced fashion (most notably because the JHE editors were not 
contacted at all during the editing process to check any of the
 essential premises of the article or to offer any type of response or
 statement)," Huang told The Scientist in an Email. "We are also apologizing for any confusion we may have
 caused in taking the Web site down."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies